Acylin Therapeutics
Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
Launch date
Market cap
-
Enterprise valuation
CAD11—16m (Dealroom.co estimates Jun 2012.)
Seattle Washington (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$4.4m | Series A | ||
N/A | $2.0m | Series A | |
Total Funding | CAD8.7m |
Related Content
Recent News about Acylin Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.